‘New Biogen’ promised as investors spurn results and estimates

13 February 2024
biogen_large

Shares in Biogen (Nasdaq: BIIB) slumped by 6% during Tuesday morning’s trading in New York.

The US biotech major had just presented its financial results for the fourth quarter and full year for 2023, as well as giving its estimates for the year ahead.

Biogen’s fourth quarter revenue of $2.39 billion was 6% lower than the same period of 2022 and missed analysts’ modest expectations for a figure of $2.47 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology